PureTech Health Cuts Karuna Therapeutics Stake to 20.4%

PureTech Health PLC said Thursday that it has cut its stake in Boston-based Karuna Therapeutics to 20.4%, raising $200 million in cash.
PureTech, a Boston-based, London-listed biotechnology company, said it sold 2.1 million Karuna shares to Goldman Sachs Group, after which it continues to hold 5.3 million shares in the Nasdaq-listed company. PureTech continues to have a right to royalty payments on net sales of any commercialized product covered by a license granted to Karuna, it said.
PureTech said the sale provides it with additional cash to fund its growth.

https://www.marketscreener.com/PURETECH-HEALTH-PLC-22619613/news/PureTech-Health-Cuts-Karuna-Therapeutics-Stake-to-20-4-29879222/